NeoGenomics, Inc. (NASDAQ:NEO) Given Average Recommendation of “Buy” by Analysts
NeoGenomics, Inc. (NASDAQ:NEO) has received a consensus rating of “Buy” from the eleven research firms that are covering the firm, Marketbeat.com reports. Two investment analysts have rated the stock with a hold recommendation, eight have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $20.63.
A number of equities analysts have weighed in on NEO shares. BidaskClub cut shares of Walgreens Boots Alliance from a “sell” rating to a “strong sell” rating in a research report on Monday, June 24th. Zacks Investment Research cut shares of GENEL ENERGY PL/ADR from a “buy” rating to a “hold” rating in a research report on Tuesday, May 7th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $10.00 price objective (down from $15.00) on shares of Nabriva Therapeutics in a research report on Wednesday, May 1st.
In other news, VP Jennifer Balliet sold 30,000 shares of the stock in a transaction dated Friday, May 3rd. The shares were sold at an average price of $22.74, for a total transaction of $682,200.00. Following the transaction, the vice president now owns 39,529 shares of the company’s stock, valued at $898,889.46. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider William Bonello sold 7,200 shares of the stock in a transaction dated Monday, May 6th. The stock was sold at an average price of $23.53, for a total transaction of $169,416.00. Following the transaction, the insider now directly owns 13,935 shares in the company, valued at approximately $327,890.55. The disclosure for this sale can be found here. Over the last three months, insiders sold 338,876 shares of company stock valued at $7,674,362. 8.80% of the stock is currently owned by corporate insiders.
NASDAQ:NEO traded down $0.62 on Friday, reaching $22.24. The stock had a trading volume of 336,592 shares, compared to its average volume of 909,548. The company has a current ratio of 1.59, a quick ratio of 1.46 and a debt-to-equity ratio of 0.35. The stock’s 50-day moving average price is $22.56. The company has a market cap of $2.14 billion, a PE ratio of 171.04 and a beta of 0.78. NeoGenomics has a 12-month low of $11.05 and a 12-month high of $24.84.
NeoGenomics (NASDAQ:NEO) last posted its quarterly earnings data on Tuesday, April 30th. The medical research company reported $0.05 earnings per share for the quarter, beating analysts’ consensus estimates of $0.02 by $0.03. The company had revenue of $95.60 million during the quarter, compared to analysts’ expectations of $89.71 million. NeoGenomics had a negative net margin of 0.14% and a positive return on equity of 3.07%. The firm’s revenue for the quarter was up 50.8% on a year-over-year basis. During the same period in the prior year, the company posted $0.04 EPS. As a group, equities analysts predict that NeoGenomics will post 0.18 EPS for the current fiscal year.
NeoGenomics, Inc, together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories in the United States; and laboratories in Switzerland and Singapore. It operates in two segments, Clinical Services and Pharma Services. The company's laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, academic centers, and other clinical laboratories.
Featured Article: Bollinger Bands
Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.com's FREE daily email newsletter.